Sobi buys AstraZeneca's RSV virus drug for $1.5bn - pharmaphorum
Sobi buys AstraZeneca's RSV virus drug for $1.5bn pharmaphorum
Sobi has completed the acquisition of AstraZeneca's Synagis (palivizumab) for $1.5 billion, plus certain conditional payments.
Comments
Post a Comment